AstraZeneca Advances Breztri Inhaler for Asthma Treatment
AstraZeneca is making big moves with its inhaler, Breztri Aerosphere, aiming to expand its use beyond chronic obstructive pulmonary disease (COPD) to also treat asthma. This could bring the company closer to its sales goal of $3 to $5 billion a year. Breztri is a 3-in-1 inhaler that combines three drugs to help people breathe
